Dolutegravir-based regimen for maintenance of viral suppression in people living with HIV: 48-week results in real-life setting
To evaluate the efficacy, safety, and tolerability of switching to a dolutegravir (DTG)-based
regimen in a cohort of virological suppressed HIV-infected patients who have previously …
regimen in a cohort of virological suppressed HIV-infected patients who have previously …
[HTML][HTML] Effectiveness and Tolerability of Dual Therapy with Dolutegravir Plus Darunavir/cobicistat in Treatment-Experienced Patients with HIV: A 144-Week Follow-Up
SW Kim, HW Jang, HH Chang, Y Kim… - Infection & …, 2024 - ncbi.nlm.nih.gov
Background A dual regimen with dolutegravir plus cobicistat-boosted darunavir (DTG+
DRV/c) is a promising alternative for patients with human immunodeficiency virus (HIV) with …
DRV/c) is a promising alternative for patients with human immunodeficiency virus (HIV) with …
[PDF][PDF] Efficacy, safety and tolerability of dolutegravir-based combination antiretroviral therapy in clinical practice in HIV-infected patients: Results from a multicenter …
Objective: Dolutegravir (DTG) is a second-generation integrase inhibitor (INI) characterized
by unboosted daily dosing, limited cross resistance, and a high barrier to resistance. We …
by unboosted daily dosing, limited cross resistance, and a high barrier to resistance. We …
Dolutegravir monotherapy versus dolutegravir/abacavir/lamivudine for virologically suppressed people living with chronic human immunodeficiency virus infection: the …
L Hocqueloux, F Raffi, T Prazuck… - Clinical Infectious …, 2019 - academic.oup.com
Background We investigated whether dolutegravir (DTG) monotherapy could be used to
maintain virological suppression in people living with human immunodeficiency virus (HIV) …
maintain virological suppression in people living with human immunodeficiency virus (HIV) …
Comparative safety and changes in immunologic and virologic parameters of dolutegravir versus efavirenz-based antiretroviral therapies among HIV Patients: A …
MA Ayal, AB Berha - HIV/AIDS-Research and Palliative Care, 2023 - Taylor & Francis
Background In combination with other two antiretroviral drugs, an efavirenz (EFV) or
dolutegravir (DTG)-based regimen is the treatment of choice for human immunodeficiency …
dolutegravir (DTG)-based regimen is the treatment of choice for human immunodeficiency …
Effectiveness of dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients
R Nasreddine, E Florence, B Vandercam, M Moutschen… - AIDS, 2020 - journals.lww.com
Objective: To describe the treatment outcomes of patients receiving dolutegravir (DTG) in a
'real-world setting'in Belgium. Design: Retrospective, observational, multicenter cohort …
'real-world setting'in Belgium. Design: Retrospective, observational, multicenter cohort …
Efficacy and safety of two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 virologically suppressed people living with HIV
C Dueñas-Gutiérrez, L Buzón, R Pedrero-Tomé… - Viruses, 2023 - mdpi.com
Background: The high effectiveness and safety of the two-drug (2DRs) strategy using
dolutegravir (DTG) plus lamivudine (3TC) have led to international guidelines …
dolutegravir (DTG) plus lamivudine (3TC) have led to international guidelines …
Effectiveness of once/day dolutegravir plus boosted darunavir as a switch strategy in heavily treated patients with human immunodeficiency virus
Study Objective Dual therapy with once/day dolutegravir (DTG) plus boosted darunavir
(DRV/b) may be a suitable and effective strategy with a high genetic barrier to resistance in …
(DRV/b) may be a suitable and effective strategy with a high genetic barrier to resistance in …
Predictors of virological failure in HIV‐1‐infected patients switching to dolutegravir maintenance monotherapy
IEA Wijting, SL Rutsaert, C Rokx, DM Burger… - HIV …, 2019 - Wiley Online Library
Objectives The Dolutegravir Monotherapy for HIV (DOMONO; NCT 02401828) study showed
that maintenance monotherapy with dolutegravir (DTG) is associated with virological failure …
that maintenance monotherapy with dolutegravir (DTG) is associated with virological failure …
Effectiveness and safety of dolutegravir two‐drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta‐analysis of real …
YS Punekar, D Parks, M Joshi, S Kaur, L Evitt… - HIV …, 2021 - Wiley Online Library
Objectives Dolutegravir (DTG) is widely recommended within three‐drug regimens.
However, similar efficacy and tolerability have also been achieved with DTG within two‐drug …
However, similar efficacy and tolerability have also been achieved with DTG within two‐drug …